Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integrative analysis of patient-derived tumoroids and ex vivo organoid modelling of ARID1A loss in bladder cancer reveals therapeutic molecular targets

30 Jan 2025

Abstract excerpt

Somatic mutations in ARID1A (AT-rich interactive domain-containing protein 1A) are present in approximately 25 % of bladder cancers (BC) and are associated with poor prognosis. With a view to discover effective treatment options for ARID1A-deficient BC patients, we set out to identify targetable effectors dysregulated consequent to ARID1A deficiency. Integrative analyses of ARID1A depletion in normal organoids...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Chromatin Remodeling and Cancer
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39892702
DOI: 10.1016/j.canlet.2025.217506

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrative analysis of patient-derived tumoroids and ex vivo organoid modelling of ARID1A loss in bladder cancer reveals therapeutic molecular targetsPMID 39892702Read ↗

Integrative analysis of patient-derived tumoroids and ex vivo organoid modeling of ARID1A loss in bladder cancer reveals therapeutic molecular targetsSemantic proximity Read ↗

Therapeutic significance of ARID1A mutation in bladder cancer.Semantic proximity Read ↗

Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer.Semantic proximity Read ↗

Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response.Semantic proximity Read ↗

ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitorsSemantic proximity Read ↗

ARID1A Alterations Are Associated with FGFR3-Wild Type, Poor-Prognosis, Urothelial Bladder TumorsSemantic proximity Read ↗

ARID1A-mutant and deficient bladder cancer is sensitive to EZH2 pharmacologic inhibitionSemantic proximity Read ↗

ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC.Semantic proximity Read ↗

A CRISPR/Cas9-Engineered ARID1A-Deficient Human Gastric Cancer Organoid Model Reveals Essential and Nonessential Modes of Oncogenic Transformation.Semantic proximity Read ↗

SWI/SNF Alterations Define a Chromatin-Dependent Subtype of Urothelial CarcinomaSemantic proximity Read ↗

ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?Semantic proximity Read ↗

Rewiring E2F1 with classical NHEJ via APLF suppression promotes bladder cancer invasivenessSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.